Insmed, Inc. (NASDAQ:INSM) Shares Bought by Cwm LLC

Cwm LLC raised its position in Insmed, Inc. (NASDAQ:INSM) by 24.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,052 shares of the biopharmaceutical company’s stock after buying an additional 404 shares during the period. Cwm LLC’s holdings in Insmed were worth $157,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Elequin Capital LP purchased a new position in Insmed in the 4th quarter worth approximately $28,000. NBC Securities Inc. purchased a new position in Insmed in the 1st quarter worth approximately $49,000. Versant Capital Management Inc lifted its stake in Insmed by 546.3% in the 1st quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 590 shares in the last quarter. GAMMA Investing LLC lifted its stake in Insmed by 62.0% in the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 386 shares in the last quarter. Finally, National Bank of Canada FI lifted its stake in Insmed by 9.7% in the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 147 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts have weighed in on INSM shares. Bank of America raised their target price on shares of Insmed from $94.00 to $109.00 and gave the stock a “buy” rating in a research note on Wednesday, June 11th. Morgan Stanley raised their target price on shares of Insmed from $102.00 to $108.00 and gave the stock an “overweight” rating in a research note on Thursday, July 17th. UBS Group decreased their target price on shares of Insmed from $110.00 to $109.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Royal Bank Of Canada lifted their price target on shares of Insmed from $99.00 to $106.00 and gave the company an “outperform” rating in a research report on Wednesday, June 11th. Finally, Wells Fargo & Company lifted their price target on shares of Insmed from $119.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday, July 22nd. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and a consensus target price of $109.20.

Insmed Stock Down 2.1%

Shares of NASDAQ INSM opened at $101.75 on Tuesday. The firm has a market cap of $19.30 billion, a price-to-earnings ratio of -17.10 and a beta of 0.90. The company has a quick ratio of 5.44, a current ratio of 5.86 and a debt-to-equity ratio of 11.38. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $106.83. The business’s 50 day moving average is $91.25 and its two-hundred day moving average is $80.16.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The firm had revenue of $92.82 million during the quarter, compared to analysts’ expectations of $91.63 million. Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The firm’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.06) EPS. Research analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Transactions at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the business’s stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total value of $9,264,648.24. Following the sale, the insider owned 89,407 shares of the company’s stock, valued at $8,352,401.94. The trade was a 52.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO William Lewis sold 6,830 shares of the business’s stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $102.37, for a total transaction of $699,187.10. Following the completion of the transaction, the chief executive officer owned 233,924 shares of the company’s stock, valued at approximately $23,946,799.88. This trade represents a 2.84% decrease in their position. The disclosure for this sale can be found here. Insiders sold 606,597 shares of company stock worth $55,120,762 in the last ninety days. 3.00% of the stock is owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.